HUTCHMED analyst targets stay high, shares trade well below consensus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:20.

HUTCHMED (China) Ltd (US44842L1035) continues to trade on NASDAQ at a marked discount to prevailing analyst targets. The ADR last closed around the 10 dollar mark, while recent consensus still points to levels above 20 dollars according to external data.

What recent data shows

Stockscan.io puts the latest closing price for Hutchmed China Limited ADR at 10.15 dollars, with the 52-week high at 19.50 dollars, almost double the current level. The ADR trades on NASDAQ in the U.S. market, giving international investors dollar-based exposure to the Chinese-focused biotech group.

The spread between the current price and last year’s high underlines the volatility typical for mid-cap biotech names. At a market capitalization of around 1.76 billion dollars reported by TradingKey, HUTCHMED sits between early-stage developers and large global pharma peers such as AstraZeneca or Novartis.

Analyst consensus remains elevated

According to Stockscan’s analyst aggregation, the average price target for HUTCHMED ADR stands at 21.07 dollars, implying more than 100 percent upside from the current 10.15 dollars. The highest target is reported at 24.47 dollars, with the lowest at 17.67 dollars, still well above the latest close.

This spread suggests a broadly constructive view on the company’s pipeline among covering analysts. The same dataset cites a longer-term 2026 target scenario with an average of 27.84 dollars, though such multi-year forecasts are inherently uncertain and should be read as indicative rather than precise. For orientation, the present price sits near the lower end of the 50-day trading range reported by MarketBeat, which lists a band between roughly 10 and 16 dollars. MarketBeat’s HUTCHMED overview provides additional consensus context.

The product behind the stock

HUTCHMED develops and commercializes oncology and immunology medicines, with a focus on innovative targeted therapies for cancer and immune disorders. Key assets include small-molecule inhibitors and biologic candidates aimed at hematological diseases and solid tumors, often co-developed or co-commercialized with larger pharma partners.

Where the stock trades today

The HUTCHMED (China) Ltd ADR shares (US44842L1035) last traded on NASDAQ at 10.15 US dollars as of 2026-06-23, 16:00 Eastern time.

This text is for informational purposes only and does not constitute investment advice, recommendation or solicitation to buy or sell any security. All data were obtained from sources believed to be reliable but cannot be guaranteed.